CRISPR Therapeutics AG
NASDAQ:CRSPBiotechnology
+$1.43 today
- Market cap
- $3.90B
- Beta
- 1.70
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$5.92
Volume 3.97M
Average 1.70M
CRSP Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
CRISPR Therapeutics AGNASDAQ: CRSP
Capital Expenditures · Q3 FY2026 · quarter ended Sep 2026
Capital expenditures turns positive
Q3 FY2026 capital expenditures was $2.06M, compared with -$74K a year earlier. Trailing-twelve-month capital expenditures was -$2.08M. Over 3 fiscal years it compounded at -70.9% a year.
Context
- Capital expenditures amounted to 26.0% of revenue in FY2025, up 20.6 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly capital expenditures holds near $2.06M or moves back toward the trailing-twelve-month quarterly average of -$520.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (914K) USD
- Year-over-year change
- +51.9%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (914K) | +51.9% |
| FY2024 | 2024-12-31 | (1.9M) | +79.9% |
| FY2023 | 2023-12-31 | (9.47M) | +74.5% |
| FY2022 | 2022-12-31 | (37.19M) | +54.5% |
| FY2021 | 2021-12-31 | (81.71M) | — |
Capital Expenditures vs competitors
How CRSP compares with its peers on the latest reported figures
- CRSP's LTM Sep 2026 capital expenditures of $2.08M is the 4th largest of the 7 companies compared; the peer median is $1.61M.
- Its year-over-year change of +220.0% is the highest of 7, against a peer median of -80.5%.
- Capital expenditures amounts to 8.3% of revenue for CRSP, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.3M | -72.7% | -47.3% | 12.2% | |
| LTM Jun 2026 | $13.39M | +24.6% | -32.7% | 8.6% | |
| LTM Mar 2026 | $2.63M | -9.6% | -57.2% | 3.0% | |
| LTM Sep 2026 | $2.08M | +220.0% | -70.9% | 8.3% | |
| LTM Mar 2026 | $585K | -91.7% | -47.2% | 1.5% | |
| LTM Mar 2026 | $473K | -88.2% | -53.7% | 0.7% | |
| LTM Mar 2026 | $54K | -89.3% | -70.5% | 0.1% | |
| Peer median (excluding CRSP) | $1.61M | -80.5% | -50.5% | 2.3% | |
Competitors are the stored peer set for CRSP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 377.66M | (650.18M) | (153.61M) | (366.25M) | (581.6M) |
| Depreciation & Amortization | 17.95M | 24.17M | 19.84M | 19.26M | 19.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 102.39M | 97.95M | 81.03M | 86.57M | 72.5M |
| Change in Working Capital | 26.86M | 19.85M | (193.59M) | 156.27M | 71.88M |
| Accounts Receivables | (161K) | 305K | (200M) | 175M | 25M |
| Inventory | (37.51M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 37.51M | 5.16M | (20.25M) | 0 | 44.89M |
| Other Working Capital | 27.02M | 14.38M | 26.66M | (18.73M) | 1.99M |
| Other Non-Cash Items | 14.11M | 12.47M | (14.05M) | (38.62M) | 72.73M |
| Operating Cash Flow | 538.97M | (495.74M) | (260.38M) | (142.77M) | (345.01M) |
| Capital Expenditures | (81.71M) | (37.19M) | (9.47M) | (1.9M) | (914K) |
| Acquisitions (Net) | 953.73M | 221.47M | 0 | 0 | 0 |
| Purchases of Investments | (1.51B) | (1.42B) | (1.07B) | (1.49B) | (1.01B) |
| Sales of Investments | 555.6M | 1.2B | 1.45B | 1.21B | 1.01B |
| Other Investing Activities | (953.73M) | (221.47M) | (2.5M) | 0 | (34M) |
| Investing Cash Flow | (1.04B) | (258.66M) | 374.65M | (280.48M) | (31.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 213.27M | 970K | 62.66M | 300.7M | 426.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 37.68M | 37.62M | 0 | 31.29M | 0 |
| Financing Cash Flow | 250.95M | 38.59M | 62.66M | 331.98M | 426.03M |
| Effect of Forex Changes | (11K) | (80K) | 656K | (21K) | 95K |
| Net Change in Cash | (245.52M) | (715.88M) | 177.59M | (91.29M) | 49.3M |
| Free Cash Flow | 457.27M | (532.93M) | (269.85M) | (144.68M) | (345.93M) |
CRISPR Therapeutics AG
NASDAQ:CRSP
Intrinsic Alpha fair value
Locked
Current Price
$40.19
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.